- Record: found
- Abstract: found
- Article: not found
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
Klaus P Hoeflich
1 ,
Carol O'Brien ,
Zachary Boyd ,
Guy Cavet ,
Steve Guerrero ,
Kenneth Jung ,
Tom Januario ,
Heidi Savage ,
Elizabeth Punnoose ,
Tom Truong ,
Wei Zhou ,
Leanne Berry ,
Lesley Murray ,
Lukas Amler ,
Marcia Belvin ,
Lori S Friedman ,
Mark R Lackner
Jul 15 2009
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The pathways underlying basal-like breast cancer are poorly understood, and as yet, there is no approved targeted therapy for this disease. We investigated the role of mitogen-activated protein kinase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) inhibitors as targeted therapies for basal-like breast cancer.
Related collections
Author and article information
Comments
Comment on this article
scite_
0
0
0
0
Smart Citations0
0
0
0
Citing PublicationsSupportingMentioningContrasting
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.